摘要
目的分析治疗复发或难治性小细胞肺癌当中,应用伊立替康联合奈达铂以及伊立替康联合顺铂二线治疗的效果。方法选取该院2016年5月—2017年5月期间收治的56例复发或难治性小细胞肺癌患者及其病历资料为观察对象,统计和观察患者采取伊立替康联合奈达铂(IN组)与伊立替康联合顺铂(IC组)治疗的效果、毒副作用情况。结果 IN组患者的肿瘤总缓解率为37.9%,患者6个月生存率为72.4%,1年生存率为27.5%;IC组患者肿瘤总缓解率为44.4%,患者6个月生存率为70.3%,1年生存率为27.5%,以上结果对比,差异无统计学意义(P>0.05),此外患者治疗不良反应率对比,差异无统计学意义(χ~2=0.635,P>0.05)。结论治疗复发或难治性小细胞肺癌过程中,以伊立替康联合铂类药物治疗可取得较好的效果,其联合奈达铂治疗,患者可耐受毒副作用,与联合顺铂治疗对比,同样有良好的效果与安全性。
Objective To analyze the effect of irinotecan combined with nedaplatin and irinotecan combined with cisplatin in the second-line therapy of recurrent or refractory small cell lung cancer. Methods 56 cases of patients with recurrent or refractory small cell lung cancer admitted and treated in our hospital from May 2016 to May 2017 were selected, and the effect and side and toxic effect of the IN group and of the IC group were compared. Results The total relief rate, 6-month survival rate, 1-year survival rate in the IN group and in the IC group were respectively 37.9%, 72.4%, 27.5% and 44.4%, 70.3%, 27.5%, and the differences between groups were not statistically significant(P>0.05), besides, the difference in the incidence rate of adverse reactions between groups was not statistically significant(χ^2=0.635,P> 0.05). Conclusion The effect of irinotecan combined with cisplatin in the therapy of recurrent or refractory small cell lung cancer is better, and the effect and safety of the irinotecan combined with nedaplatin are also good.
作者
王密
李海波
WANG Mi;LI Hai-bo(Department of Respiration Medicine,Chongqing Donghua Hospital,Chongqing,400000 China)
出处
《系统医学》
2018年第22期34-35,38,共3页
Systems Medicine
关键词
伊立替康
奈达铂
顺铂
复发或难治性小细胞肺癌
毒副作用
Irinotecan
Nedaplatin
Cisplatin
Recurrent or refractory small cell lung cancer
Side and toxic effects
